Viswa Colluru, Enveda CEO
November 21, 2024 08:46 PM ESTUpdated 07:04 AM
Financing
Startups

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Kyle LaHucik

Senior Reporter

Biotech start­up Enve­da has raised a $130 mil­lion Se­ries C, the Col­orado com­pa­ny said Thurs­day morn­ing.

Found­ed and led by ear­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Dur­ing Covid, RFK Jr. lob­bied against vac­cine EUAs for chil­dren. As HHS sec­re­tary, he could re­scind them

Can­del’s shares soar on Phase 3 prostate can­cer da­ta de­spite un­clear prospects

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times